================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: April 22, 2004
QLT Inc.
------------------------------------------------------
(Exact name of registrant as specified in its Charter)
British Columbia, Canada 000-17082 N/A
- ------------------------ ------------ -------------------
(Jurisdiction of (Commission (IRS Employer
Incorporation) File Number) Identification No.)
QLT Inc.,
887 Great Northern Way,
Vancouver, B.C., CANADA, V5T 4T5
(604) 707-7000
----------------------------------------------------
(Address, including zip code, and telephone number,
including area code, of principal executive offices)
================================================================================
ITEM 5. OTHER EVENTS
On April 22, 2004, QLT Inc. reported that its alliance partner,
Novartis, announced global Visudyne(R) (verteporfin) sales of
approximately US$101.1 million for the quarter ended March 31,
2004. This represents an increase of 23% over sales in the first
quarter of 2003.
ITEM 7. EXHIBITS
Exhibit
Number Description
- ------- -----------
99.1 Press release dated April 22, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
QLT Inc.
----------------------
(Registrant)
Date April 22, 2004 /s/ Paul J. Hastings
--------------------------- -------------------------------------
(Signature)
President and Chief Executive Officer